At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBE INVESCO BIOTECHNOLOGY & GENOME ETF
Market Closed 08-07 16:00:00 EDT
92.76
+1.64
+1.80%
盘后92.74
-0.02-0.02%
19:34 EDT
High92.76Low91.48Vol27.05K
Open92.08D1 Closing91.12Amplitude1.41%
Mkt Cap351.57MTradable Cap351.57MTotal Shares3.79M
T/O2.49MT/O Rate0.71%Tradable Shares3.79M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab
TIPRANKS  ·  21:01
Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab
Amgen SVP, Chief Compliance Officer Nancy Grygiel Sells 2,970 Shares for $1.2 Million
Reuters  ·  06:46
Amgen SVP, Chief Compliance Officer Nancy Grygiel Sells 2,970 Shares for $1.2 Million
Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio
Reuters  ·  05:12
Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.
Dow Jones  ·  00:36
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.
Grail announces FDA advisory committee meeting to review Galleri test PMA
TIPRANKS  ·  08-07 23:10
Grail announces FDA advisory committee meeting to review Galleri test PMA
Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense
Reuters  ·  08-07 20:44
Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense
Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-07 16:30
Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors
Biogen completes acquisition of RayThera
TIPRANKS  ·  08-07 06:55
Biogen completes acquisition of RayThera
Biogen Completes Acquisition of RayThera
Reuters  ·  08-07 06:33
Biogen Completes Acquisition of RayThera
Biogen Completes Acquisition of Raythera Inc.
THOMSON REUTERS  ·  08-07 06:15
Biogen Completes Acquisition of Raythera Inc.
Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook
Reuters  ·  08-07 04:11
Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook
Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River
TIPRANKS  ·  08-07 00:59
Vortex Energy Study Confirms Major Salt Structure and New Target at Robinsons River
Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story
TIPRANKS  ·  08-07 00:41
Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story
Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop
Dow Jones  ·  08-06 22:46
Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)
TIPRANKS  ·  08-06 20:10
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)
Royalty Pharma price target raised to $70 from $66 at Citi
TIPRANKS  ·  08-06 18:41
Royalty Pharma price target raised to $70 from $66 at Citi
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Reuters  ·  08-06 18:11
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook
Reuters  ·  08-06 04:53
Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook
Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge
Reuters  ·  08-06 04:46
Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge
Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million
Reuters  ·  08-06 04:44
Tenaya Net Loss Widens to $43.39 Million in Q2 FY26; R&D Expenses Slip to $16.6 Million

Introduction

Company Name.
INVESCO BIOTECHNOLOGY & GENOME ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Issue price:
--